Stocks

Spruce Biosciences SPRB

Health care sectorNasdaq

What to see in Spruce Biosciences now

Is Wall Street adding or cutting?+31

63 13F filers hold it · +31 against the quarter before · shares held +168.4%

Holdings of 06/30
Who bought more than 5%?4.8%

Orbimed Advisors holds 4.8%

Filed 08/14
What comes next?10/16 (Fri)

10/16 estimated earnings

Due 10/16

Company

Exchange
Nasdaq
Industry
Pharmaceutical Preparations
Headquarters
South San Francisco, California
Fiscal year end
12/31
Next earnings
10/16, estimated
  • 63 13F filers hold it · +31 against the quarter before · shares held +168.4%Holdings of 06/30
  • Orbimed Advisors holds 4.8%Filed 08/14

Funds

13F filers: 63 · +31 since the quarter before · 06/30 holdings

Famous funds that held Spruce Biosciences in their latest 13F report.

FundValueSince the quarter before
Mirae Asset Global ETFS HoldingsSpruce Biosciences SPRB · 06/30 holdings$67.6KNo quarter before
All tracked funds

5% stakes

Holder
Orbimed Advisors08/144.8%132,200 shFirst report
ADAR1 Capital Management08/142.5%67,717 sh−2.9pp
Citadel Advisors08/141.9%51,919 sh−3.2pp
AWM Investment Company08/145.1%146,988 shFirst report
Integrated Core Strategies08/045.8%160,981 sh−3.8pp
BlackRock07/306.8%187,836 shFirst report
Orin Hirschman07/279.1%250,000 shFirst report
Citadel Advisors05/155.1%70,065 sh−1.4pp
Alyeska Investment Group05/154.49%61,670 sh−1.3pp
Squadron Capital Management05/150.9%12,200 sh−5.6pp
Wellington Management Group05/153.6%48,796 sh−1.9pp
Ikarian Capital05/074.8%121,356 sh−6.6pp
ExodusPoint Capital Management04/280.8%22,000 shFirst report
Integrated Core Strategies02/249.6%103,026 shFirst report
Carlyle Group02/184.7%50,893 shNo earlier report
ADAR1 Capital Management02/175.4%58,000 shFirst report
Alyeska Investment Group02/175.79%61,670 shFirst report
Citadel Advisors02/176.5%70,035 sh−3.5pp
Wellington Management Group02/105.5%58,949 shFirst report
Peter David Boone25/11/246.4%68,184 shFirst report
All 5% stake reports on Spruce Biosciences

26-week trading